{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:47:29Z","timestamp":1774615649900,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T00:00:00Z","timestamp":1432944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s12282-015-0618-7","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T00:14:58Z","timestamp":1432858498000},"page":"649-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses"],"prefix":"10.1007","volume":"23","author":[{"given":"Hiroshi","family":"Nakagomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Hirotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Amemiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,30]]},"reference":[{"key":"618_CR1","unstructured":"Monitering of Cancer Incidence in Japan MCIJ 2010. http:\/\/ganjoho.jp\/data\/professional\/statistics\/backnumber\/2013\/fig01.pdf . Accessed 6 Dec 2014."},{"key":"618_CR2","unstructured":"NCCN Clinical Practice Guidelines in Oncology, High-risk genetic\/familial assessment in breast and ovary. Version 2012. http:\/\/www.tri-kobe.org\/nccn\/guideline\/gynecological\/english\/genetic_familial.pdf . Accessed 6 Dec 2014."},{"key":"618_CR3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00439-013-1299-y","volume":"132","author":"L Melchor","year":"2013","unstructured":"Melchor L, Benitez J. The complex genetic landscape of familial breast cancer. Hum Genet. 2013;132:845\u201363.","journal-title":"Hum Genet"},{"key":"618_CR4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117\u201330.","journal-title":"Am J Hum Genet"},{"key":"618_CR5","doi-asserted-by":"publisher","DOI":"10.11111\/cge.12315","author":"JM Bowless","year":"2013","unstructured":"Bowless JM, Eggingto KR, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clini Genet. 2013;. doi: 10.11111\/cge.12315 .","journal-title":"Clini Genet"},{"key":"618_CR6","unstructured":"Yoshimoto T. Research progress in hereditary breast cancer tests to know the risks. http:\/\/www.tokyo-np.co.jp\/article\/living\/health\/CK2014112502000185.html . Accessed 14 Nov 2014."},{"key":"618_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mgg3.120","volume":"3","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu Y, Nakagomi H, Sakamoto I, et al. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med. 2015;3:121\u20139.","journal-title":"Mol Genet Genomic Med"},{"key":"618_CR8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66\u201371.","journal-title":"Science"},{"key":"618_CR9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789\u201392.","journal-title":"Nature"},{"key":"618_CR10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480\u201390.","journal-title":"J Clin Oncol"},{"key":"618_CR11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"MC King","year":"2001","unstructured":"King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251\u20136.","journal-title":"JAMA"},{"key":"618_CR12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.bjc.6600064","volume":"86","author":"SW Duffy","year":"2002","unstructured":"Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer. 2002;86:218\u201321.","journal-title":"Br J Cancer"},{"key":"618_CR13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van \u2018t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055\u201362.","journal-title":"J Clin Oncol"},{"key":"618_CR14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","volume":"26","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093\u20137.","journal-title":"J Clin Oncol"},{"key":"618_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10147-004-0423-3","volume":"9","author":"M Arai","year":"2004","unstructured":"Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9:270\u201382.","journal-title":"Int J Clin Oncol."},{"key":"618_CR16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12282-013-0477-z","volume":"21","author":"H Bando","year":"2014","unstructured":"Bando H. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan. Breast Cancer. 2014;21:656\u201363.","journal-title":"Breast Cancer."},{"key":"618_CR17","unstructured":"Bando H, Shimizu C,Yamamoto S, Mizota Y, Katou T. Current situation Survay on provision of information about hereditary breast by Japanese physician to young breast cancer patients (abstract) J Japan Soc Clin Oncol. 2011;452;MS1\u20136."},{"key":"618_CR18","unstructured":"Genetic Information Non-Discrimination Act of 2008. H.R. 493, 110th Cong:2007\u20132008."},{"key":"618_CR19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","volume":"25","author":"JM Lee","year":"2014","unstructured":"Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32\u201340.","journal-title":"Ann Oncol"},{"key":"618_CR20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852\u201361.","journal-title":"Lancet Oncol."},{"key":"618_CR21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382\u201392.","journal-title":"N Engl J Med"},{"key":"618_CR22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852\u201361.","journal-title":"Lancet Oncol."},{"key":"618_CR23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/510454a","volume":"510","author":"H Ledford","year":"2014","unstructured":"Ledford H. Resurrected cancer drug faces regulators. Nature. 2014;510:454.","journal-title":"Nature"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-015-0618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-015-0618-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-015-0618-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T12:40:58Z","timestamp":1559565658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-015-0618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,30]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1007\/s12282-015-0618-7","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,30]]}}}